Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease

Publication | Closed Access

DOI

124

Citations

References

2003

Year

Ralph Zinner, Bonnie S. Glisson, Frank V. Fossella, Katherine M.W. Pisters, Merril Kies, Pamela M. Lee, Erminia Massarelli, Bradley S. Sabloff, Herbert A. Fritsche, Jae Y. Ro,

Lung Cancer

OncologyPhase Ii TrialPathologyBronchial NeoplasmHer2-overexpressing DiseaseOptimal IdentificationCancer TreatmentMedicineRadiation OncologyLung Cancer